Implantica hosts Capital Markets Day in Stockholm after RefluxStop FDA approval

• Implantica hosted a Capital Markets Day in Stockholm on Sept. 9, 2026, outlining its U.S. rollout strategy for RefluxStop following FDA clearance.
• Management detailed commercial and marketing plans for the U.S. market opportunity, supported by external surgeon perspectives on clinical adoption.
• The program also provided a European market update, alongside physician and patient testimonials aimed at reinforcing real-world procedure outcomes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Implantica AG published the original content used to generate this news brief via Cision (Ref. ID: 202609110850BITN____UKPR__EN_20260911-BIT-9364-0) on September 11, 2026, and is solely responsible for the information contained therein.